Protalix BioTherapeutics said Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in two investor conferences in New York City from September 14-16, 2026. He is due to present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14 at 2:00 p.m. EDT and take part in a Morgan Stanley 24th Annual Global Healthcare Conference fireside chat on September 16 at 1:05 p.m. EDT. The Morgan Stanley event will be webcast live, with an archived replay available afterward. Protalix develops and manufactures rare-disease treatments, including the enzyme replacement therapies Elfabrio and Elelyso, using its ProCellEx plant cell-based expression system. Its pipeline includes PRX-115, PRX-119 and research programs in rare renal diseases.